BCR-ABL T315I: how one gatekeeper mutation defeated three generations of drugs

Chronic myeloid leukemia is the success story of targeted therapy: imatinib turned a fatal disease into a manageable one by shutting down the BCR-ABL kinase. But a single mutation, T315I, became the emblem of drug resistance in oncology. It swaps a threonine at the gatekeeper position for an isoleucine, and in doing so it removes a hydrogen bond the drug relied on and adds a small bump the drug cannot fit around. That was enough to knock out imatinib, dasatinib, and nilotinib in one move.

What the gatekeeper residue does

The gatekeeper sits at the entrance to a hydrophobic pocket next to the ATP site. Its identity controls what can slip past it into that back pocket. In BCR-ABL the wild-type gatekeeper is threonine 315, and its side-chain hydroxyl makes a hydrogen bond that several inhibitors, imatinib included, use as an anchor. Threonine is also relatively small, leaving room for a drug to reach the pocket behind it.

Why isoleucine breaks so many drugs at once

T315I does two things simultaneously. First, isoleucine has no hydroxyl group, so the hydrogen bond that anchored the drug is gone. Second, isoleucine is bulkier than threonine, so it juts into the path a drug takes toward the back pocket and sterically blocks it. A drug that depended on either the hydrogen bond or the open channel now fails, and imatinib, dasatinib, and nilotinib depended on both to varying degrees. This is why T315I is called a pan-resistance mutation: it does not defeat one drug's specific contact, it removes a feature the whole inhibitor class was built against.

How ponatinib got back into the pocket

Ponatinib was engineered specifically for T315I. Instead of threading past the gatekeeper, it uses a carbon-carbon triple bond (an alkyne linker) that is linear and slim enough to slide past the bulky isoleucine without clashing, and it does not depend on the lost hydrogen bond. That structural idea is why ponatinib remains the reference inhibitor for T315I-positive disease, and it shows the general principle: beating a gatekeeper mutation usually means redesigning the part of the molecule that passes the gate, not just boosting affinity elsewhere. The allosteric inhibitor asciminib, which binds a different site entirely, is another route around the same problem.

Seeing the shift by docking

T315I is a clean case to study by docking because the mechanism is geometric: a lost contact plus a steric bump. Dock imatinib into wild-type BCR-ABL and into a T315I model and the mutant pose comes out worse, because the docking search cannot recover the anchoring interaction and has to place the molecule around the larger side chain. Dock ponatinib into the same pair and the gap is far smaller. Running wild-type against mutant side by side is a quick way to ask whether a scaffold is gatekeeper-tolerant before you invest in it.

Try it on the mutation

Open Studio and dock a BCR-ABL inhibitor against wild-type and a T315I pocket in one run. Liganx is mutation-aware molecular docking online: free and browser-based, so you can compare wild-type versus mutant binding and rank the shift to prioritize which scaffolds are worth testing against a resistant kinase. It is a fast first pass, not a final potency verdict.

Primary sources

• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias (PACE). N Engl J Med 369, 1783-1796 (2013). doi:10.1056/NEJMoa1306494
• Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quintas-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 118, 293-299 (2012). doi:10.1002/cncr.26225